Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G1 to S phase transition 1 pseudogene (ENSG00000255065) is annotated as a pseudogene in the human genome. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they are typically not transcribed or translated into functional proteins. Unlike their functional counterparts involved in the G1/S transition of the cell cycle—such as key cyclins (cyclin D, E), cyclin-dependent kinases (CDKs), and retinoblastoma (Rb) protein—this pseudogene does not appear to play a direct role in cell cycle regulation or serve as a therapeutic target. Pseudogenes can sometimes regulate their functional gene homologs through RNA-mediated mechanisms (as competitive endogenous RNAs or through other epigenetic means), but no direct or clinically relevant function is established or referenced for this specific pseudogene[8]. Key context: - The phrase “G1 to S phase transition” refers to a critical point in the cell cycle essential for DNA replication and cell proliferation[1][2][3]. Many protein-coding genes regulate this transition and are potential therapeutic targets in oncology and regenerative medicine[1][2][3]. However, ENSG00000255065 is only a pseudogene, not a functional protein, enzyme, receptor, or other targetable molecule. - Pseudogenes are generally not considered drug targets and are often noted only as genomic annotations[8]. If you require information about the functional “G1 to S phase transition protein 1” (GSPT1), which is implicated in translation and apoptosis, please clarify, as that is a distinct, protein-coding entity[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G1 to S phase transition 1 pseudogene.